- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06192160
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (RAD-TB)
A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary tuberculosis (TB).
A5409 hypothesizes that novel regimens for the treatment of pulmonary tuberculosis will result in superior early efficacy, as determined by longitudinal mycobacteria growth indicator tube (MGIT) liquid culture time to positivity (TTP) measurements over the first 6 weeks of treatment, and will have acceptable safety and tolerability over 8 weeks of treatment relative to standard of care [(SOC) isoniazid/rifampicin/pyrazinamide/ethambutol (HRZE)].
The study will run for 52 weeks, inclusive of 26 weeks of TB treatment comprised of 8 weeks of experimental or SOC treatment (based on treatment arm assignment) followed by 18 weeks of SOC treatment with 45 participants in each experimental treatment arm and at least 90 participants in the SOC arm.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Radojka Savic, PharmD, PhD
- Phone Number: 415-502-0640
- Email: rada.savic@ucsf.edu
Study Contact Backup
- Name: Kelly Dooley, MD, PhD
- Phone Number: 615-322-8972
- Email: kelly.e.dooley@vumc.org
Study Locations
-
-
-
Gaborone, Botswana, 0000
- 12701, Gaborone CRS
-
Contact:
- Unoda Chakalisa
- Phone Number: 267-393-1353
- Email: uchakalisa@bhp.org.bw
-
-
-
-
-
Porto Alegre, Brazil, 91350
- 12201, Hospital Nossa Senhora da Conceicao CRS
-
Contact:
- Rita Lira
- Phone Number: +55 51-33572603
- Email: lrita@ghc.com.br
-
Rio De Janeiro, Brazil, 21040
- 12101, Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS
-
Contact:
- Brenda Hoagland
- Phone Number: 55 21 38659122
- Email: brenda.hoagland@ipec.fiocruz.br
-
-
-
-
-
Port-au-Prince, Haiti, 6110
- 30022, Les Centres GHESKIO Clinical Research Site (GHESKIO-INLR) CRS
-
Contact:
- Samuel Pierre
- Phone Number: 509-37407711
- Email: spierre@gheskio.org
-
Port-au-Prince, Haiti, 6110
- 31730, GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS
-
Contact:
- Yvetot Joseph
- Phone Number: 509 29401431
- Email: yvetotjoseph@gheskio.org
-
-
-
-
-
Pune, India, 411001
- 31441, Byramjee Jeejeebhoy Medical College (BJMC) CRS
-
Contact:
- Nishi Suryavanshi
- Phone Number: 91-9823248979
- Email: nishisuryavanshi@hotmail.com
-
-
-
-
-
Eldoret, Kenya, 30100
- 12601, Moi University Clinical Research Center (MUCRC) CRS
-
Contact:
- Voila Kirui
- Phone Number: 254-711-729856
- Email: viola.kirui@gmail.com
-
Kericho, Kenya, 20200
- 12501, Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS
-
Contact:
- Samwel Chirchir
- Phone Number: +254 52-20 36100
- Email: samwel.chirchir@usamru-k.org
-
-
-
-
-
Blantyre, Malawi, 265
- 30301, Blantyre CRS
-
Contact:
- Dumisile Huwa
- Phone Number: 265-811885
- Email: dhuwa@jhp.mw
-
Lilongwe, Malawi, A-104
- 12001, Malawi CRS
-
Contact:
- Thokozani Makuhunga
- Phone Number: 265-175-5056
- Email: tmakuhunga@unclilongwe.org
-
-
-
-
-
Mexico City, Mexico, 14080
- 32078, Nutrición-Mexico CRS
-
Contact:
- Brenda Crabtree
- Phone Number: 52-5550682274
- Email: brenda.crabtree@infecto.mx
-
-
-
-
-
Lima, Peru, 1010
- 11301, Barranco CRS
-
Contact:
- Consuelo Tristan
- Phone Number: +51 1-206-7800
- Email: ctristan@impactaperu.org
-
-
-
-
-
Cavite, Philippines, 4114
- 31981, De La Salle Health Science Institute Angelo King Medical Research Center (DLSHSI-AKMRC)
-
Contact:
- Maria Gler
- Phone Number: +63 917-823-0431
- Email: msgler@my.dlshsi.edu.ph
-
-
-
-
-
Cape Town, South Africa, 6850
- 31793, South African Tuberculosis Vaccine Initiative (SATVI) CRS
-
Contact:
- Lynnett Stone
- Phone Number: +27 23-346-5400
- Email: lynnett.stone@uct.ac.za
-
Cape Town, South Africa, 7700
- 31792, University of Cape Town Lung Institute (UCTLI) CRS
-
Contact:
- Catrien Drinkwater
- Phone Number: +27 21-4066850
- Email: catrien.drinkwater@uct.ac.za
-
Durban, South Africa, 40001
- 31422, CAPRISA eThekwini CRS
-
Contact:
- Nivashnee Naicker
- Phone Number: 27-0-31 655 0658
- Email: Bongi.zuma@caprisa.org
-
Durban, South Africa, 4091
- 11201, Durban International CRS
-
Contact:
- Rosie Mngqibisa
- Phone Number: 27-31-2611093
- Email: mngqibisa@ecarefoundation.com
-
Johannesburg, South Africa, 1864
- 12301, Soweto ACTG CRS
-
Contact:
- Suri Moonsamy
- Phone Number: +27-11-989-9905
- Email: moonsamys@phru.co.za
-
Johannesburg, South Africa, 2193
- 11101, University of the Witwatersrand Helen Joseph (WITS HJH) CRS
-
Contact:
- Betty Matome
- Phone Number: +27 11-276-8800
- Email: bmatome@witshealth.co.za
-
Rustenburg, South Africa
- 31684, Rustenburg CRS
-
Contact:
- Tiro Dinake
- Phone Number: 27-723-968-940
- Email: tdinake@auruminstitute.org
-
-
-
-
-
Chiang Mai, Thailand, 50200
- 31784, Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS
-
Contact:
- Daralak Tavornprasit
- Phone Number: 66 5393 6148
- Email: daralak.t@cmu.ac.th
-
Pathum Wan, Thailand, 10330
- 31802, Thai Red Cross AIDS Research Centre (TRC-ARC) CRS
-
Contact:
- Parawee Thongpaeng
- Phone Number: 66-2-6523040
- Email: parawee.t@hivnat.org
-
-
-
-
-
Kampala, Uganda, 10005
- 12401, Joint Clinical Research Centre (JCRC)/Kampala CRS
-
Contact:
- Sandra Rwambuya
- Phone Number: 256-417-723-000
- Email: dxr23@case.edu
-
-
-
-
-
Harare, Zimbabwe, 30313
- 30313, Milton Park CRS
-
Contact:
- Patience Sibanda
- Phone Number: 263-774-361-790
- Email: psibanda@uz-ctrc.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pulmonary TB (among individuals either without history of prior TB treatment or with history of TB treatment more than 5 years prior to study entry), identified within 7 days prior to study entry by at least one sputum specimen positive for Mtb by Xpert. Semiquantitative Mtb results of "medium" or "high" are required.
- Pulmonary TB with documented INH susceptibility (by Line Probe Assay (LPA) or Xpert MTB/XDR or other validated molecular test) and with documented RIF susceptibility (by LPA or Xpert MTB/RIF or Xpert MTB/RIF Ultra or other validated molecular test) within 7 days prior to study entry.
Documentation of HIV-1 infection status, as below:
Presence or Absence of HIV-1 infection, as documented by:
- Any licensed rapid HIV test or HIV-1 enzyme or chemiluminescence immunoassay (E/CIA) test kit, any time prior to study entry. AND
Confirmed by one of the following:
- A second antibody test from different manufacturers or based on different principles and epitopes (combination antigen-antibody-based rapid tests may be used), or
- HIV-1 antigen, or
- Plasma HIV-1 RNA viral load, or
- A licensed Western blot
- For individuals with HIV: CD4+ cell count ≥100 cells/mm3 based on testing performed within 30 days prior to study entry.
- For individuals with HIV: Currently being treated with dolutegravir-based antiretroviral therapy (ART), or plan to initiate dolutegravir-based ART at or before study week 8.
- Individuals age ≥18 years.
The following laboratory values obtained within 7 days prior to study entry at any network-approved non-US laboratory that operates in accordance with Good Clinical Laboratory Practices (GCLP) and participates in appropriate external quality assurance programs:
- Serum or plasma alanine aminotransferase (ALT) ≤3 times the upper limit of normal (ULN)
- Serum or plasma total bilirubin ≤2 times ULN
- Serum or plasma creatinine ≤2 times ULN
- Serum or plasma potassium ≥3.5 mEq/L
- Serum or plasma magnesium ≥1.0 mEq/L (≥0.500 mmol/L)
- Absolute neutrophil count (ANC) ≥1500/mm^3
- Hemoglobin ≥9.5 g/dL for individuals assigned to female sex at birth and ≥10.0 g/dL for individuals assigned to male sex at birth
- Platelet count ≥100,000/mm^3
- Negative for hepatitis B core antibody (HBcAb) total, hepatitis B surface antigen (HBsAg)
- Negative for hepatitis C virus (HCV) antibody (or if HCV antibody positive, must have a negative HCV PCR)
For individuals assigned to female sex at birth and who are of reproductive potential, negative pregnancy test (urine HCG or serum β-HCG) within 3 days (72 hours) prior to entry by any network-approved non-US laboratory or clinic that operates in accordance with GCLP and participates in appropriate external quality assurance programs.
Individuals assigned to female sex at birth, who are of reproductive potential, and who participate in sexual activity that could lead to pregnancy must agree to use at least two of the following forms of birth control while receiving TB study medications and for 12 months after stopping study medications:
- Male or female condoms
- Diaphragm or cervical cap (with spermicide, if available)
- Intrauterine device (IUD) or intrauterine system (IUS)
- Hormone-based birth control (e.g., oral contraceptives, Depo-Provera, NuvaRing, implants)
- For individuals who are assigned male sex at birth who engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives. They are also strongly advised to inform their non-pregnant sexual partners of reproductive potential to use effective contraceptives while the individual is on study and for 90 days after experimental treatment discontinuation.
- For individuals assigned male sex at birth with pregnant partners, willingness to use condoms during vaginal intercourse while on study and for 90 days after experimental treatment discontinuation.
- For individuals assigned male sex at birth, willingness to refrain from sperm donation while on study and for 90 days after experimental treatment discontinuation.
- Documentation of Karnofsky performance score ≥60 obtained within 14 days prior to study entry.
- Chest x-ray obtained within 14 days prior to study entry.
- A verifiable address or residence readily accessible for visiting, and willingness to inform the study team of any change of address during study treatment and follow-up period.
- Ability and willingness of individual to provide informed consent.
Exclusion Criteria:
- More than cumulative 7 days of treatment directed against active TB for the current TB episode in the 60 days preceding study entry.
- Current extrapulmonary TB, in the opinion of the investigator.
- QTcF interval >450 ms within 7 days prior to study entry.
- History of or ongoing heart failure.
- Personal or family history of congenital QT prolongation.
- History of known, untreated, ongoing hypothyroidism.
- History of or ongoing bradyarrhythmia.
- History of torsades de pointes.
- Current Grade 2 or higher peripheral neuropathy.
- Other medical conditions (e.g., diabetes, liver or kidney disease, blood disorders, chronic diarrhea), in the opinion of the site investigator, in which the current clinical condition of the participant is likely to prejudice the response to, or assessment of, treatment.
- Pregnant or breastfeeding or planning to become pregnant within the next 12 months.
- Weight <35 kg.
- Unable to take oral medications.
- Taking any of prohibited medications.
- Known allergy/sensitivity or any hypersensitivity to components of investigational agents or their formulation.
- Active drug or alcohol use or dependence; or mental illness (e.g., major depression) that, in the opinion of the site investigator, would interfere with adherence to study requirements.
- Taking an investigational drug or vaccine within 30 or more days prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1: Standard of Care (SOC)
|
INH 300 mg will be administered as one tablet orally once daily.
Other Names:
RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
Other Names:
PZA will be administered as 500 mg tablets, based on weight, orally once daily.
Other Names:
EMB will be administered as 400 mg tablets, based on weight, orally once daily.
Other Names:
|
Experimental: Arm 2: Bedaquiline (BDQ), Pretomanid (Pa), and Linezolid (LZD)
|
INH 300 mg will be administered as one tablet orally once daily.
Other Names:
RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
Other Names:
BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
Other Names:
Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
Other Names:
LZD 600 mg will be administered as one 600 mg tablet orally once daily.
Other Names:
|
Experimental: Arm 3A: BDQ, Pa and TBI-223 (1200 mg)
|
INH 300 mg will be administered as one tablet orally once daily.
Other Names:
RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
Other Names:
BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
Other Names:
Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
Other Names:
TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
|
Experimental: Arm 3B: BDQ, Pa and TBI-223 (2400 mg)
|
INH 300 mg will be administered as one tablet orally once daily.
Other Names:
RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
Other Names:
BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
Other Names:
Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
Other Names:
TBI-223 2400 mg once daily will be administered as four 600 mg tablets orally once daily with a meal.
TBI-223 1200 mg once daily will be administered as two 600 mg tablets orally with a meal.
|
Experimental: Arm 4A: BDQ, Pa and Sutezolid (SZD) (800 mg)
|
INH 300 mg will be administered as one tablet orally once daily.
Other Names:
RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
Other Names:
BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
Other Names:
Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
Other Names:
SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
Other Names:
SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
Other Names:
|
Experimental: Arm 4B: BDQ, Pa and SZD (1600 mg)
|
INH 300 mg will be administered as one tablet orally once daily.
Other Names:
RIF 600 mg will be administered as two 300 mg capsules orally once daily on an empty stomach, 1 hour before or 2 hours after eating a meal.
Other Names:
BDQ 400 mg will be administered as four 100 mg tablets orally once daily with a meal for the first 2 weeks followed by 200 mg (two 100 mg tablets) orally once daily with a meal for 6 weeks.
Other Names:
Pa 200 mg will be administered as one 200 mg tablet orally once daily with a meal.
Other Names:
SZD 1600 mg once daily will be administered as four 400 mg tablets orally once daily with a meal.
Other Names:
SZD 800 mg once daily will be administered as two 400 mg tablets orally once daily with a meal.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in mean log10 (Time to positivity (TTP)) slope from longitudinal mycobacteria growth indicator tube (MGIT) liquid culture measurements over the first 6 weeks of treatment
Time Frame: Weeks 0, 1, 2, 3, 4 and 6
|
for each experimental treatment arm compared to the SOC arm.
|
Weeks 0, 1, 2, 3, 4 and 6
|
Difference in the cumulative proportion of participants having at least one new Grade 3 or higher adverse event (AE) by week 8 of treatment
Time Frame: 8 weeks
|
for each experimental treatment arm compared to the SOC arm.
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cumulative proportion of participants with stable sputum culture conversion by week 8 as measured by culture-negative status via MGIT liquid culture at two consecutive measurements.
Time Frame: 8 weeks
|
8 weeks
|
Mean log10 TTP slope from longitudinal MGIT liquid culture measurements over the first 8 weeks of treatment.
Time Frame: Weeks 0, 1, 2, 3, 4, 6 and 8
|
Weeks 0, 1, 2, 3, 4, 6 and 8
|
Cumulative proportion of participants with a new Grade 3 or higher AE by week 26 of treatment.
Time Frame: 26 weeks
|
26 weeks
|
Cumulative proportion of participants with permanent discontinuation of study-provided anti-TB drugs due to any reason prior to Week 8 of treatment.
Time Frame: 8 weeks
|
8 weeks
|
Cumulative proportion of participants with permanent discontinuation or temporary discontinuation for ≥3 days of at least one anti-TB drug due to any reason prior to week 8 of treatment.
Time Frame: 8 weeks
|
8 weeks
|
Cumulative proportion of participants with permanent discontinuation of at least one anti-TB drug due to any reason prior to week 26 of treatment.
Time Frame: 26 weeks
|
26 weeks
|
A composite of stable culture conversion at week 6 of treatment and no new Grade 3 or higher AE through week 8.
Time Frame: 8 weeks
|
8 weeks
|
Proportion of participants with durable cure by 52 weeks after treatment initiation.
Time Frame: 52 Weeks
|
52 Weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Radojka Savic, PharmD, PhD, University of California
- Study Chair: Kelly Dooley, MD, PhD, Vanderbilt University Medical Center
- Study Chair: Gustavo Velásquez, MD, MPH, University of California
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Lung Diseases
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Tuberculosis, Pulmonary
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites
- Hypolipidemic Agents
- Lipid Regulating Agents
- Anti-Bacterial Agents
- Leprostatic Agents
- Protein Synthesis Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- Antitubercular Agents
- Antibiotics, Antitubercular
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C8 Inducers
- Cytochrome P-450 CYP2C19 Inducers
- Cytochrome P-450 CYP2C9 Inducers
- Fatty Acid Synthesis Inhibitors
- Linezolid
- Rifampin
- Bedaquiline
- Isoniazid
- Pyrazinamide
- Ethambutol
- Oxazolidinones
Other Study ID Numbers
- A5409
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
- With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.
- For what types of analyses? To achieve aims in the proposal approved by the AIDS Clinical Trials Group.
- By what mechanism will data be made available? Researchers may submit a request for access to data using the AIDS Clinical Trials Group "Data Request" form at: https://actgnetwork.org/submit-a-proposal/. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Tuberculosis
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Tjip van der WerfGadjah Mada University; The Enose Company, Zutphen the NetherlandsCompletedPulmonary Tuberculosis Suspected | Other Specified Chronic Obstructive Pulmonary Disease | Pulmonary Tuberculosis TB (+) Histology, (-) BacteriologyIndonesia
-
Research Institute of Epidemiology, Microbiology...Active, not recruitingAspergillosis | Pulmonary Tuberculoses | Old Tuberculosis | Active Tuberculosis | Chronic Pulmonary AspergillosisUzbekistan
-
Medecins Sans Frontieres, NetherlandsLondon School of Hygiene and Tropical Medicine; University of Liverpool; Ministry... and other collaboratorsCompletedMulti-drug Resistant Tuberculosis | Pulmonary Tuberculoses | Extensively Drug-Resistant TuberculosisBelarus, South Africa, Uzbekistan
-
Radboud University Medical CenterEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Department... and other collaboratorsCompletedPulmonary Tuberculosis (TB)South Africa
-
National Institute of Allergy and Infectious Diseases...International Tuberculosis Research CenterWithdrawnRefractory Pulmonary TuberculosisKorea, Republic of
-
Assiut UniversityUnknownExtra Pulmonary Tuberculosis
-
Karolinska InstitutetAddis Ababa University; Armauer Hansen Research Institute, EthiopiaCompleted
-
Assistance Publique - Hôpitaux de ParisUnknownPulmonary Tuberculosis | Extra Pulmonary TuberculosisFrance
Clinical Trials on Isoniazid
-
Instituto Nacional de Salud Publica, MexicoWithdrawnDiabetes Mellitus | Latent Tuberculosis
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Federal University... and other collaboratorsRecruitingTuberculosis Infection | Isoniazid Adverse ReactionBrazil
-
National Institute of Allergy and Infectious Diseases...CompletedHIV Infections | TuberculosisHaiti, South Africa, Thailand, Tanzania, Botswana, Zimbabwe, India, Uganda
-
Hospital Universitari de BellvitgeCellestisCompletedLatent Tuberculosis InfectionSpain
-
National Taiwan University HospitalUnknownLatent Tuberculosis InfectionTaiwan
-
National Institute on Drug Abuse (NIDA)Johns Hopkins UniversityUnknown
-
Asan Medical CenterCompleted
-
University of CologneTerminatedPulmonary TuberculosisGermany, Bulgaria, Poland
-
University of Cape TownLondon School of Hygiene and Tropical Medicine; Johns Hopkins University; Imperial... and other collaboratorsCompletedHIV Infections | Tuberculosis | Latent Tuberculosis InfectionSouth Africa
-
Makerere UniversityRecruiting